117 related articles for article (PubMed ID: 38520128)
21. Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
Younis IR; Hsueh CH; Nelson C; Billin AN; Yue MS; Xiao D; Watkins TR; Othman AA
J Clin Pharmacol; 2023 Sep; 63(9):1017-1025. PubMed ID: 37128693
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
24. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
25. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
J Clin Pharmacol; 2015 Aug; 55(8):944-52. PubMed ID: 25821156
[TBL] [Abstract][Full Text] [Related]
26. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
[TBL] [Abstract][Full Text] [Related]
28. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
Dandan M; Han J; Mann S; Kim R; Li K; Mohammed H; Chuang JC; Zhu K; Billin AN; Huss RS; Chung C; Myers RP; Hellerstein M
J Lipid Res; 2023 Mar; 64(3):100339. PubMed ID: 36737040
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
Shimasaki Y; Sakaki M; Itou M; Kobayashi T; Aso M; Kagawa T; Saiki T; Matsuno K; Sano Y; Shimizu K; Kuroda S; Koumura E
Clin Drug Investig; 2018 Nov; 38(11):1041-1051. PubMed ID: 30194585
[TBL] [Abstract][Full Text] [Related]
30. Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
Zahir H; Greenberg J; Hsu C; Marbury TC; Lasseter KC; Xu LA; Tap WD; Healey JH; Stacchiotti S; LaCreta F
J Clin Pharmacol; 2022 Aug; 62(8):992-1005. PubMed ID: 35247274
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
[TBL] [Abstract][Full Text] [Related]
32. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
Barbour AM; Rockich K; Cimino E; Zhou G; Leonetti-Whalen C; Chen X; Yeleswaram S; Epstein N; Punwani N
J Clin Pharmacol; 2021 Jul; 61(7):954-960. PubMed ID: 33434286
[TBL] [Abstract][Full Text] [Related]
33. Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam.
Kletzl H; Ajmi H; Antys I; Heinig K; Jaber B; Marbury TC; Young A; Günther A
Br J Clin Pharmacol; 2022 Aug; 88(8):3749-3759. PubMed ID: 35301746
[TBL] [Abstract][Full Text] [Related]
34. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study.
Bergman A; Carvajal-Gonzalez S; Tarabar S; Saxena AR; Esler WP; Amin NB
Clin Pharmacol Drug Dev; 2020 May; 9(4):514-526. PubMed ID: 32065514
[TBL] [Abstract][Full Text] [Related]
35. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Lawendy N; Lamba M; Chan G; Wang R; Alvey CW; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Safety of Vilazodone in Hepatic Impairment.
Boinpally R; Henry D; Gupta S; Edwards J; Longstreth J; Periclou A
Am J Ther; 2015; 22(4):269-77. PubMed ID: 25474324
[TBL] [Abstract][Full Text] [Related]
37. Brivaracetam disposition in mild to severe hepatic impairment.
Stockis A; Sargentini-Maier ML; Horsmans Y
J Clin Pharmacol; 2013 Jun; 53(6):633-41. PubMed ID: 23649964
[TBL] [Abstract][Full Text] [Related]
38. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.
Bruderer S; Detishin V; Tsvitbaum N; Dingemanse J
Br J Clin Pharmacol; 2011 Jan; 71(1):52-60. PubMed ID: 21143501
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
